Welcome to our dedicated page for HALOZYME THERAPEUTICS SEC filings (Ticker: HALO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Halozyme Therapeutics, Inc. filings document the company's drug-delivery business, royalty-based collaboration model, governance actions and capital-market disclosures. 8-K reports cover financial results and guidance, executive officer appointments and compensation arrangements, bylaw amendments, and annual meeting voting results.
Proxy materials describe board elections, executive compensation, equity awards, auditor ratification and stockholder voting mechanics. Filings also provide formal disclosure around ENHANZE, Hypercon and Surf Bio technology portfolio updates, partnered commercial products, and acquisition-related operating updates when reported by the company.
HALOZYME THERAPEUTICS, INC. (HALO) completed a private offering of $1,500.0 million aggregate principal amount of 1.50% Convertible Senior Notes due 2033, including $200.0 million from the initial purchasers’ option, issued under an indenture with The Bank of New York Mellon Trust Company, N.A. as trustee.
The company received $1,471.1 million of net proceeds, using about $187.5 million to enter into capped call transactions and expecting to use portions to repurchase $151.7 million of its 0.25% 2027 notes and $220.0 million of its 1.00% 2028 notes, with remaining proceeds earmarked for general corporate purposes and potential future note repurchases. The notes bear 1.50% interest, are convertible at an initial rate of 7.1509 shares per $1,000 (conversion price about $139.84), and are subject to various conversion, redemption, repurchase and default provisions. Capped call transactions, with an initial cap of $208.39 per share (about 90.0% above the September 17, 2026 close), are intended to reduce potential dilution or offset cash payments above principal upon conversion.
Halozyme Therapeutics, Inc. (HALO) priced an upsized private offering of $1.3 billion aggregate principal amount of 1.50% convertible senior notes due 2033, with an additional $200 million option for initial purchasers. The notes are senior unsecured, pay 1.50% interest semi-annually, and are offered only to qualified institutional buyers.
The notes have an initial conversion rate of 7.1509 shares per $1,000, equivalent to a conversion price of $139.84, a 27.5% premium to the $109.68 closing stock price on September 17, 2026. Halozyme expects net proceeds of about $1.275 billion (or $1.471 billion if the option is fully exercised).
The company plans to use approximately $162.5 million of proceeds to enter into capped call transactions with a cap price of about $208.39, and to repurchase about $151.7 million of 2027 notes and $220.0 million of 2028 notes for total cash costs of roughly $217.0 million and $435.5 million, respectively. Remaining proceeds are earmarked for general corporate purposes and potential additional note repurchases.
HALOZYME THERAPEUTICS, INC. (HALO) director Matthew L. Posard reported selling a total of 18,996 shares of common stock on September 16, 2026 in four open-market transactions. The sales, at weighted average prices between about $106 and $109 per share, were made under a Rule 10b5-1 trading plan adopted June 15, 2026.
HALOZYME THERAPEUTICS, INC. (HALO) reports that director Matthew Posard has filed a notice to sell 34,226 shares of common stock under Rule 144 through Morgan Stanley Smith Barney LLC. The shares were acquired via vesting of restricted stock units between June 5, 2015 and May 5, 2022.
The notice lists an aggregate market value of $3,636,512.50 for the shares to be sold and indicates that there are 113,498,000 shares of common stock outstanding.
Halozyme Therapeutics, Inc. (HALO) plans a private offering, subject to market conditions and other factors, of $1.05 billion aggregate principal amount of convertible senior notes due 2033, with an expected $150 million option for initial purchasers to buy additional notes. The notes will be senior, unsecured obligations maturing on October 1, 2033, convertible under specified conditions before April 1, 2033 and at any time thereafter until shortly before maturity. Halozyme expects to enter into capped call transactions to offset potential conversion dilution and plans to use part of the net proceeds to pay for these capped calls and to repurchase portions of its existing 0.25% convertible notes due 2027 and 1.00% convertible notes due 2028, with the remainder for general corporate purposes and possible future note repurchases or repayments.
HALOZYME THERAPEUTICS, INC. (HALO) reported that President and CEO Helen Torley exercised stock options for 60,000 shares of common stock at an exercise price of $18.41 per share over September 9–11, 2026, and sold 60,000 shares at weighted average prices around $107 per share under a pre-arranged Rule 10b5-1 trading plan.
HALOZYME THERAPEUTICS, INC. (HALO) reported that director Dannielle Appelhans received equity-based compensation on September 1, 2026. She was granted 1,161 Restricted Stock Units, each representing one common share, and options to purchase 1,778 shares of common stock at an exercise price of $107.72 per share. Both the RSUs and the stock options are scheduled to vest in full on the date of Halozyme’s 2027 annual meeting of stockholders. No Rule 10b5-1 trading plan is reported for these awards.
HALOZYME THERAPEUTICS, INC. (HALO) filed an initial statement of beneficial ownership for director Dannielle Appelhans. The Form 3 indicates her status as a director but does not report any specific equity holdings or transactions at this time. The filing also includes an Exhibit 24 Power of Attorney authorization.
HALOZYME THERAPEUTICS, INC. (HALO) reported that President and CEO Helen Torley exercised stock options and sold common shares under a pre-arranged Rule 10b5-1 trading plan. Over August 17–19, 2026, she exercised options for 60,000 shares at $18.41 per share and sold 60,000 common shares in multiple open-market transactions at weighted-average prices generally between the high $90s and about $108 per share. The options exercised were part of a ten-year grant originally awarded in February 2018 and expiring in February 2028.
Halozyme Therapeutics, Inc. (HALO) reported a board change. On August 14, 2026, Dannielle Appelhans was elected to the company’s Board of Directors. She joins the class of directors whose terms end at the 2028 annual meeting of stockholders and was not initially assigned to any board committee.
Appelhans will receive cash retainers plus restricted stock and stock option awards under Halozyme’s standard director compensation program for non-employee directors, as previously described in the proxy statement for the 2026 annual meeting held on May 5, 2026. The company states there are no special arrangements related to her election and no related person transactions with her.